News Controversial diabetes drug not associated with increased CV risk in patients with CAD Treatment with rosiglitazone was not associated with an increased risk of major ischemic cardiovascular events in a large, international study of patients with type 2 diabetes and coronary artery disease. "Our analyses did not detect any ... » clinicalendocrinologynews/specialty-focus/diabetes/single-article-page/controversial-diabetes-drug-not-associated-with-increased-cv-risk-in-patients-with-cad/
Posted on: Mon, 12 Aug 2013 02:48:12 +0000
Trending Topics
Recently Viewed Topics
© 2015